Gilead Sciences GILD
NASDAQ GILD
$146.01 -0.63 (-0.43%)
As of: Sep 9, 2026 · 1:25 PM EDT

Gilead Sciences (GILD) Long-Term Debt Issuances (2009 - 2026)

Gilead Sciences' (GILD) quarterly Long-Term Debt Issuances came in at $1.3 billion in Q2 2026, up 14555.56% on a YoY basis from N/an in Q2 2025, and down 52.31% quarter-over-quarter from $2.8 billion in Q1 2026.

Analysis

Gilead Sciences (GILD) Long-Term Debt Issuances (2009 - 2026) Analysis & Trends

Gilead Sciences (GILD) has reported Long-Term Debt Issuances for 18 consecutive years, with $1.3 billion the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Long-Term Debt Issuances rose 14555.56% year-over-year to $1.3 billion; the trailing twelve-month figure through Jun 2026 stood at $4.1 billion (up 21.22% YoY), and the FY2025 full-year result was $1.8 billion, down 48.38% from the prior year.
  • Long-Term Debt Issuances slipped to $1.3 billion in Q2 2026 per GILD's latest filing, from $2.8 billion in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $2.8 billion in Q1 2026 and bottomed at $8.0 million in Q4 2025.
  • Historically, Long-Term Debt Issuances has averaged $1.1 billion across 5 years, with a median of $1.2 billion in 2022.
  • The sharpest annual moves came in 2025 and 2026: Long-Term Debt Issuances slumped 99.51% in 2025, then surged 14555.56% in 2026.
  • Over 5 years, Long-Term Debt Issuances stood at $1.0 billion in 2022, then surged by 125.0% to $2.2 billion in 2023, then tumbled by 33.29% to $1.5 billion in 2024, then sank by 99.47% to $8.0 million in 2025, then jumped by 16387.5% to $1.3 billion in 2026.
  • According to Business Quant data, Long-Term Debt Issuances over the past three periods registered $1.3 billion, $2.8 billion, and $8.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Amgen 211.51 Bn 197.52 Bn 7.24 Bn -
2 Gilead Sciences 181.48 Bn 178.30 Bn 6.22 Bn 1.32 Bn
3 Vertex Pharmaceuticals 132.45 Bn 124.60 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.87 Bn 74.88 Bn 3.93 Bn -
5 Argenx Se 61.59 Bn 56.41 Bn 1.37 Bn -
6 Moderna 54.72 Bn 49.59 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.13 Bn 30.82 Bn 992.69 Mn -
8 Biogen 31.29 Bn 30.01 Bn 1.96 Bn -
9 Roivant Sciences 30.31 Bn 30.31 Bn 1.16 Mn -
10 Insmed 28.19 Bn 27.03 Bn 358.27 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.32 Bn
Mar 31, 2026 2.77 Bn
Dec 31, 2025 8.00 Mn
Sep 30, 2025 9.00 Mn
Jun 30, 2025 9.00 Mn
Mar 31, 2025 1.76 Bn
Dec 31, 2024 1.50 Bn
Sep 30, 2024 112.00 Mn
Jun 30, 2024 1.85 Bn
Sep 30, 2023 2.25 Bn
Sep 30, 2022 1.00 Bn
Mar 31, 2022 500.00 Mn
Dec 31, 2021 1.00 Bn
Sep 30, 2021 2.50 Bn
Mar 31, 2021 1.25 Bn
Dec 31, 2020 995.00 Mn
Sep 30, 2020 6.69 Bn
Mar 31, 2020 500.00 Mn
Sep 30, 2019 1.50 Bn
Jun 30, 2019 500.00 Mn